Latest Conference Articles

December 13th 2024, 2:20am

San Antonio Breast Cancer Symposium

Maxwell Lloyd, MD, discusses a real-world study of elacestrant outcomes based on prior treatment and ESR1 mutation status in HR+ breast cancer.

December 12th 2024, 10:30pm

San Antonio Breast Cancer Symposium

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.

December 12th 2024, 9:31pm

OncLive News Network: On Location at SABCS 2024

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

December 12th 2024, 6:43pm

San Antonio Breast Cancer Symposium

Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.

December 12th 2024, 5:56pm

San Antonio Breast Cancer Symposium

Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.

December 12th 2024, 5:00pm

San Antonio Breast Cancer Symposium

Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.

December 12th 2024, 4:42pm

ASH Annual Meeting and Exposition

Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.

December 12th 2024, 3:00pm

ASH Annual Meeting and Exposition

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

December 12th 2024, 2:05am

San Antonio Breast Cancer Symposium

Azka Ali, MD, discusses findings from the S0221 trial of alternative adjuvant anthracycline and taxane dosing schedules in high-risk, early breast cancer.

December 11th 2024, 11:48pm

OncLive News Network: On Location at SABCS 2024

Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

December 11th 2024, 10:05pm

ASH Annual Meeting and Exposition

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

December 11th 2024, 9:29pm

San Antonio Breast Cancer Symposium

Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.

December 11th 2024, 9:13pm

San Antonio Breast Cancer Symposium

Neoadjuvant patritumab deruxtecan with or without letrozole produced pathologic complete responses in high-risk, HR-positive/HER2-negative breast cancer.

December 11th 2024, 9:06pm

San Antonio Breast Cancer Symposium

SHR-A1811 monotherapy demonstrated high clinical activity and was well tolerated in patients with HER2-positive breast cancer.

December 11th 2024, 8:54pm

San Antonio Breast Cancer Symposium

Adjuvant olaparib maintained an efficacy benefit vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer.

December 11th 2024, 8:41pm

San Antonio Breast Cancer Symposium

Elacestrant plus abemaciclib demonstrated clinically important efficacy in ER-positive/HER2-negative advanced or metastatic breast cancer.

December 11th 2024, 8:35pm

San Antonio Breast Cancer Symposium

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

December 11th 2024, 7:56pm

ASH Annual Meeting and Exposition

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

December 11th 2024, 7:01pm

San Antonio Breast Cancer Symposium

Risk-reducing surgery improved survival outcomes in younger patients with breast cancer and a germline BRCA mutation.

December 11th 2024, 6:55pm

San Antonio Breast Cancer Symposium

T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.